SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys quarterly earnings beat and raised revenue outlook, driven by strong demand for Mounjaro and Zepbound, are fueling the rally and record-high discussion. Traders are broadly bullish on GLP-1 growth, while some flag the rich valuation, lower profit guidance tied to acquisition-related charges, and weaker-than-expected Foundayo sales.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, supported by growth in Dupixent and Eylea HD, sparked a sharp share-price jump and fresh highs. Traders are largely celebrating the results and breakout, while debating whether the rally can hold or will pull back.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and slightly raised its outlook, but shares sold off to a new 52-week low as traders questioned the modest growth, the contribution of an Israeli R&D grant to profitability, and the companys ability to win advanced-driving programs amid competition. The reaction is split between bearish short sellers and investors who view the cash position and autonomous-driving opportunities as support for a recovery.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high is drawing attention ahead of its expected Q3 report, with traders focused on BRIUMVIs sales momentum and guidance, plus the coming subcutaneous data. Buyout and short-squeeze theories are adding to bullish sentiment, though those remain speculation and some traders caution that strong results may already be priced in.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 results for Amgens IMDELLTRAImfinzi combination in extensive-stage small-cell lung cancer have reinforced the pipeline story as shares reach fresh highs. Traders are weighing the potential commercial impact against upcoming earnings, with some viewing put activity as a hedge rather than a bearish bet.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Traders are focused on the anticipated completion of Compass Pathways rolling NDA submission for COMP360, its investigational psilocybin therapy for treatment-resistant depression, and the potential for an expedited FDA review. Many expect the filing to be a catalyst, while others are frustrated by the delay and cautious about the share-price weakness and uncertainty around approval.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of layoffs affecting roughly 550 employees in India, with additional cuts reported in the Philippines, have raised concern that a client project is being scaled back and could signal lost revenue. Traders are split between fearing a major customer or contract loss and viewing the cuts as an efficiency move or overreaction, with many looking to the upcoming earnings report for clarification.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reached its 80th overall-survival event, triggering database lock and final analysis ahead of topline results expected in Q4. Traders are divided: bullish posts interpret the trials long duration as a possible sign of benefit from GPS, while skeptics stress that the milestone reveals no treatment-arm results and point to unresolved trial-design questions and the share-price decline.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

A Northland upgrade citing C3 Codes potential to speed development of agentic AI applications is a prominent catalyst in the discussion. Traders are split on whether the renewed optimism and call activity can overcome concerns about declining revenue and execution, while some speculate about a short squeeze.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A sharp selloff in gold has pushed GLD to a 52-week low, with traders citing expectations for a more hawkish Fed and possible forced liquidation as pressure on the metal. The move has prompted debate over golds safe-haven role: bears see more downside, while some investors are treating the drop as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Centene (CNC) Outpaced Other Medical Stocks This Year?

Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data

Equity

The biotech firm reported strong Phase 2 trial results for a blood cancer treatment, along with a $140 million fundraise to support the next stages of the trial.

Insider Signals and Potential Moonshots that Could Reset Valuations

Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP

Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses

Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside $140 million financing.read more...

Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street

$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks

Insights into Cellectar Biosciences's Upcoming Earnings

Earnings Outlook For Cellectar Biosciences

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 


All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Cellectar Biosciences Inc

Neutral Sentiment

<ul class="summary-bullets"><li>The study showed a major response rate of 61.8%, meeting its primary endpoint.</li><li>The company is preparing for potential regulatory submissions in the United States and Europe.</li><li>Cellectar’s $140 million financing includes around $35 million in upfront payment, with $105 million tied to future milestones.</li></ul>Cellectar Biosciences (CLRB) surged more than 27% on Tuesday, climbing to its highest level in more than six months, as investor optimism swelled following strong Phase 2 trial results for blood cancer treatment alongside a $140 million financing to advance the program’s next phase.The company is preparing for potential regulatory submissions in the United States and Europe.<h2 class="st-heading-2">CLRB’s Phase 2 Trial Meets Primary Endpoint</h2>Cellectar Biosciences reported strong results from its Phase 2b CLOVER WaM trial evaluating Iopofosine I 131 in patients with relapsed or refractory Waldenström macroglobulinemia (WM), a rare type of blood cancer.With at least 12 months of follow-up, the study showed an overall response rate (ORR) of 83.6% and a major response rate (MRR) of 61.8%, meeting its primary goal. MRR is a stricter parameter for evaluating disease reduction. The trial also highlighted progression-free survival of 13.5 months.The therapy also delivered strong results in patients who had previously been treated with BTK inhibitors, a type of targeted cancer therapy that blocks the growth of cancer cells. Safety remained manageable, with mostly mild side effects and low infection rates.“We remain committed to providing Iopofosine I 131 to the thousands of patients who can benefit from treatment and plan to initiate our confirmatory study in the fourth quarter of this year,” said CEO James Caruso.<h2 class="st-heading-2">CLRB’s Pipeline To Get A Boost From $140 Million Financing</h2>Separately, Cellectar Biosciences announced a financing deal that could raise up to $140 million to support its drug development efforts. The agreement includes about $35 million in upfront funding, with an additional $105 million tied to future milestones. The company will issue common stock through a registered offering, along with warrants and additional shares in a private placement.The financing round was oversubscribed and backed by several healthcare funds, including Nantahala Capital Management, Balyasny Asset Management, Caligan Partners, and Janus Henderson Investors.“This oversubscribed financing provides important validation of our strategy to pursue accelerated approval in the US and conditional marketing approval in Europe for Iopofosine, while supporting our plans to initiate a global confirmatory study in the fourth quarter of 2026,” Caruso added.<h2 class="st-heading-2">Retail Traders Expect CLRB Stock To Double In Value</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CLRB">CLRB</a> on Stocktwits changed to ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes were ‘extremely high.’One investor called the Phase 2 results “awesome” and expects the stock to climb to $7, nearly double its current value.<stembedurl>https://stocktwits.com/cjstocksup/message/652307465</stembedurl>The stock has gained around 40% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cytk-stock-gains-on-heart-disease-trial-update/cZQDPwYRe9k">CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.21
Prev Close	$1.22
Open	$1.20
Dividend Yield	0.00%
50-Day Moving Average	$1.89
Beta	1.00
Avg. Volume	63,264.41
PE Ratio	-0.26

52-Week High	$4.70
52-Week Low	$1.12
Market Capitalization	$11.39M
EPS (Annual)	-$8.35
Price to Book	0.33
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLRB Fundamentals